Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients
NCT ID: NCT01048047
Last Updated: 2010-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
88 participants
INTERVENTIONAL
2009-11-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension
NCT01080768
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
NCT00219076
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
NCT00797862
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
NCT00739973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aliskiren/amlodipine
aliskiren, 300 mg/amlodipine 10 mg
aliskiren/amlodipine
aliskiren 300 mg /amlodipine 10 mg
amlodipine
amlodipine 10 mg
aliskiren/amlodipine
aliskiren 300 mg /amlodipine 10 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aliskiren/amlodipine
aliskiren 300 mg /amlodipine 10 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* systolic blood pressure \> 140 mmHg and \< 180 mmHg
* no amlodipine therapy for the previous 6 months
Exclusion Criteria
* systolic blood pressure \> 180 mmHg
* secondary hypertension
* heart failure
* diabetes mellitus
* liver or kidney diseases
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Pavia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto Fogari, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pavia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pavia
Pavia, , Italy
University of Pavia
Pavia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2009
Identifier Type: REGISTRY
Identifier Source: secondary_id
UNIPV001DIM2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.